TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiac patients of NYHA Class II to III~* ASA class maximally 4~* Age at least 18~* Scheduled for elective, non-cardiac surgery under general anesthesia with propofol in the supine position, with planned muscle relaxation using rocuronium and allowing for 12-lead ECG assessment during surgery;~* Given written informed consent.~Exclusion Criteria:~* Disorders interfering with the reliability of the assessments (e.g. ECG measurements), such as paroxysmal atrial fibrillation or the presence of a pacemaker~* Known or suspected neuromuscular disorders impairing NMB~* Known or suspected significant renal dysfunction~* Known or suspected (family) history of malignant hyperthermia~* Known or suspected allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Intended) use of medication expected to interfere with the effect of rocuronium as given in this trial, based on the dose and/or the time of administration (such as antibiotics, anticonvulsants and Mg2+ )~* Pregnancy (pregnancy to be excluded for women both from medical history and by an hCG test within 24 h before surgery, except for women who were not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or a hysterectomy)~* Childbearing potential without using any method of birth control or using only hormonal contraception as birth control (subjects were allowed to participate if they were willing to use a condom, or a diaphragm with spermicide, or IUD, or have a vasectomized partner (\>6 months) or abstinence, for one month after participation in the trial)~* Breast -feeding~* Prior participation in any trial with Org 25969~* Participation in another clinical trial not pre -approved by Organon, within 30 days of entering into trial 19.4.309

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Sugammadex 2.0 mg/kg
- Arm 2 (Type: EXPERIMENTAL): Sugammadex 4.0 mg/kg
- Arm 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~* Chronic hepatitis C, genotype 1b-infection (HCV RNA level greater than or equal to 10,000 IU/mL at screening)~* Subject has never received antiviral treatment for hepatitis C infection~* No evidence of liver cirrhosis~Exclusion Criteria:~* Significant liver disease with any cause other than HCV as the primary cause~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody~* Positive screen for drugs or alcohol~* Significant sensitivity to any drug~* Use of contraindicated medications within 2 weeks of dosing~* Abnormal laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, Plus RBV (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
- ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Laser Acupuncture on Forearm Bone Mineral Density and Wrist Pain in Osteoporotic Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* age between 50 and 60 years~* body mass index (BMI) between 25 and 35 Kg/m2.~* Multiparas with a parity of 5 or more were included.~* They had decreased forearm BMD with T score of DEXA less than or equal to -2.5 wrist pain with visual analogue scale (VAS) ≥ 3~* natural menopause for at least four years~Exclusion Criteria:~* history of bone disease, renal, liver, endocrinal or parathyroid disorders, cardiac affection,~* using a pacemaker~* taking any drugs which may affect bone metabolism

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Drug treatment group (Type: ACTIVE_COMPARATOR): 34 postmenopausal women who only received oral calcium and vitamin D3 supplement (Calcium D3F® (Arab Company for Pharmaceutical\& medicinal plants (MEPACO-MEDIFOOD, EGPYT). Each tablet contains 1000 mg of natural calcium carbonate, 1000 IU vitamin D3 (0.025 mg) and 0.25 mg Sodium Fluoride. They received 1 tablet once daily for 12 weeks
- Drug treatment + laser acupuncture group (Type: ACTIVE_COMPARATOR): 34 postmenopausal women who received laser acupuncture therapy in addition to the same calcium and vitamin D3 supplement for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality Job Interview Training in Severe Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Over the age of 18~2. Diagnosis of any of the following:~   1. Any chronic schizophrenia spectrum disorder, including schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder, other specified schizophrenia spectrum and related disorder, and unspecified schizophrenia spectrum and related disorders;~  2. Any bipolar spectrum disorder beyond bipolar type I and II to include cyclothymia, other specified bipolar and related disorder, and unspecified bipolar and related disorders;~  3. Any depressive disorder, including disruptive mood dysregulation disorder, major depressive disorder, persistent depressive disorder, other specified depressive disorder, and unspecified depressive disorder;~  4. Posttraumatic stress disorder~3. fluency in English~4. 6th grade reading level~5. Enrolled in Supported Employment/Individual Placement Support (IPS)~6. Active IPS enrollee as indicated by at least 1 contact with his/her Employment Specialist in the past 30 days.~7. Currently unemployed or underemployed~8. Planning to go on interviews within 4 weeks of registration on study.~9. Willing to be video recorded for certain study elements.~10. Must have given signed, informed consent prior to registration on study.~Exclusion Criteria:~1. Documented developmental or learning disability.~2. Medical condition that may compromise cognition (e.g., Parkinson's Disease, Alzheimer's Disease, Huntington's Chorea, Moderate or Greater TBI).~3. Uncorrected vision or hearing problems~4. Active suicidal ideation within the last 30 days with at least some intent to act, with or without a specific plan; this would be reflected in a score of 4 or 5 on the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (CSSRS)~5. A past suicide attempt within the past 30 days that did not include preparatory acts or behavior, but was defined by a potentially self-injurious act committed with at least some wish to die as a result of the act.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virtual Reality Job Interview Training (Type: EXPERIMENTAL): Virtual Reality Job Interview Training
- Supported Employment (Services as Usual) (Type: OTHER): Supported Employment (Services as Usual)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Multiple Sclerosis (MS) subjects who have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 and a baseline Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria:~  * Have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with MS , OR~ * Show evidence of gadolinium-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to randomization.~Key Exclusion Criteria:~* Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS~* History of malignancy~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity~* History of abnormal laboratory results based on investigator judgment~* History of human immunodeficiency virus (HIV) or other immunodeficient conditions~* History of drug or alcohol abuse within the 2 years prior to randomization~* An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization~* Positive screening for active infection with Hepatitis B virus or Hepatitis C virus~* Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before Screening~* Exposure to varicella zoster virus within 21 days before Screening.~* Abnormal blood tests at Screening: Hemoglobin ≤9.0 g/dL, Platelets ≤100 × 10\^9/L, Lymphocytes ≤1.0 × 10\^9/L, Neutrophils ≤1.5 × 10\^9/L, alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase \>2 times the upper limit of normal (ULN) and serum creatinine \>ULN.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
- 150 mg DAC HYP (Type: EXPERIMENTAL): Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
- 300 mg DAC HYP (Type: EXPERIMENTAL): Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Comparison of Silicone Hydrogel Monthly Lenses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign Informed Consent;~* Best corrected visual acuity (BCVA) of at least 0.1 logarithm of the minimum angle of resolution (logMAR) in each eye at Visit 1;~* Manifest cylinder less than or equal to 0.75 diopter (D) in each eye at Visit 1;~* Successful current wearer (during the past 2 months for a minimum of 5 days per week and 8 hours per day) of monthly replacement silicone hydrogel lenses within the power range of lens powers available for the screening and study lenses;~* Screening lenses worn 10 hours exhibiting high lipid uptake.~Exclusion Criteria:~* Habitual lens used in an extended wear modality (routinely sleeping in lenses overnight for 1 night per week or more) during the past 2 months;~* Habitually wearing AIR OPTIX AQUA, AIR OPTIX plus HydraGlyde, ACUVUE OASYS®, or ACUVUE VITA as contact lenses during the past 2 months;~* Any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear (within 7 days of enrollment, or current)~* History of herpetic keratitis, corneal surgery, or irregular cornea;~* Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the Investigator;~* Abnormal ocular conditions or findings, as specified in the protocol;~* Known pregnancy and lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lotrafilcon B, then senofilcon C (Type: OTHER): Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
- Senofilcon C, then lotrafilcon B (Type: OTHER): Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phenazopyridine for Confirmation of Ureteral Patency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females only~* Planned surgical procedure where cystoscopy will be used to document ureteral urine flow~* Age \> or = 18 years, no upper age limit~* Able and willing to consent~Exclusion Criteria:~* Planned surgical procedure where cystoscopy will not be used~* Planned surgical procedure where cystoscopy is used for a purpose other than documenting ureteral urine flow~* age \<18 years~* pregnancy~* unable/unwilling to participate~* history of allergy or adverse reaction to phenazopyridine~* hepatic dysfunction~* known phenazopyridine hypersensitivity~* history of urologic surgery~* presence of ureteral stents prior to the planned surgical procedure~* concomitant suprapubic catheter placement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): No preoperative phenazopyridine
- Phenazopyridine (Type: EXPERIMENTAL): Preoperative phenazopyridine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects; 18 - 40 years of age~* Body mass index between 18 and 27 kg/m2~* Written informed consent~* Normal findings in medical \& bleeding history~* Non-smoking~Exclusion Criteria:~* Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration~* Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease)~* Known disorders with increased bleeding risk (e.g. peridontosis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer)~* Known sensitivity to common causes of bleeding (e.g. nasal)~* History of thromboembolism~* History of occlusive vascular diseases~* History of vascular anomalies~* History of hypercholesterolemia~* History of myopathy~* Impaired liver function (AST, ALT, gGT, bilirubin \> 3 x ULN)~* Impaired renal function (serum creatinine \> 1.3 mg/dl)~* Elevated creatinine-kinase or serum-myoglobin (\> 3 x ULN)~* Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis~* HIV-1/2-Ab, HbsAg or HCV-Ab positive serology~* Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg~* Known allergy against any test agent under study~* Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol~* Participation in another clinical trial during the preceding 3 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): 80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes will comply with the requirements of the protocol.~* Written informed consent obtained from the subject.~* A male or female aged 70 years or older at the time of the first vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy History of HZ.~* Previous vaccination against varicella or HZ.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation.~* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.~* Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period.~* Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine.~* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.~* Acute disease and/or fever at the time of enrolment.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zoster vaccine group (Type: EXPERIMENTAL): Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
- Placebo group (Type: PLACEBO_COMPARATOR): Subjects will receive NaCl solution placebo according to a 0, 2-month schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients were admitted to the study based on the following inclusion criteria:~1. Any age and any party.~2. Body mass index between 25 and 35.~3. Singleton pregnancy.~4. Gestational age of 24 weeks or more. Gestational age was established on the basis of menstrual dates and confirmed by first or second trimester ultrasound for booked patients, however, if a difference of \> 7 days or \> 10 days during first or second trimester respectively, then ultrasound value was used. For unbooked patients they still have the chance to be included in our study if they can bring a scan that showed gestational age during the same period mentioned before.~5. Idiopathic intrauterine growth restriction.~6. Intrauterine growth restriction due to maternal malnutrition, maternal medical disorder as anemia, pregnancy induced hypertension, or chronic renal disease.~7. Intrauterine growth restriction due to substance abuse (including smoking).~8. With or without past history of intrauterine growth restriction .~Exclusion Criteria:~1. Intrauterine growth restriction due to fetal causes as congenital abnormalities, fetal infection, or multiple gestation.~2. Any drug therapy that can affect fetal growth or fetal blood supply.~3. Maternal diseases that contraindicates the use of sildenafil citrate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- sildenafil citrate (Type: ACTIVE_COMPARATOR): 50 mg single oral dose
- placebo (Type: ACTIVE_COMPARATOR): single tablet of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete